Literature DB >> 7159277

[Intratumor immunotherapy with BCG cell wall preparations: development of a new therapy approach for head-neck tumors].

J Bier, S Kleinschuster, H Bier, H Rapp.   

Abstract

The present study deals with the influence of intratumoral injections of BCG cell-wall preparations (CWP) on the development of malignant tumors in the head-neck region. Line 10 tumor cells in strain 2 guinea pigs were used in a first assay. It became evident that intratumoral BCG-CWP injection leads to total tumor regression, a situation which can also be achieved by radical surgery. In contrast to the radically operated animals, those injected intratumorally with BCG-CWP develop a tumor-specific immunity. A second animal system was used to examine the effect of intratumoral BCG-CWP treatment on the development of autochthonous squamous cell carcinomas in cows. In this model, radical surgery leads to a clinical cure in all cases, while intratumoral BCG-CWP therapy leads to a complete clinical cure in 50% of the animals (observation period: 1 year). On the basis of experiments performed with animals systems, a clinical study was initiated to examine the effect of preoperative BCG-CWP injection in patients with squamous cell carcinomas in the head-neck region. At present, the case study involves 24 patients. The cumulative percentage of patients in complete tumor remission is now 69% for BCG-CWP pretreated tumor patients and 39% for patients who underwent surgery only. The hitherto existing life-table analyses of both therapy groups and the small degree of side effects resulting from BCG-CWP seem to justify a continuation of the study until a statistically confirmed statement can be made about the curative effect of BCG-CWP within the framework of a combination therapy in patients with squamous cell carcinomas in the head-neck region.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7159277     DOI: 10.1007/bf00454216

Source DB:  PubMed          Journal:  Arch Otorhinolaryngol        ISSN: 0302-9530


  11 in total

1.  Maximum utilization of the life table method in analyzing survival.

Authors:  S J CUTLER; F EDERER
Journal:  J Chronic Dis       Date:  1958-12

2.  Treatment of malignant melanoma by intratumoral injection of BCG.

Authors:  C M Pinsky; Y Hirshaut; H F Oettgen
Journal:  Natl Cancer Inst Monogr       Date:  1973-12

3.  Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis.

Authors:  B Zbar; I D Bernstein; G L Bartlett; M G Hanna; H J Rapp
Journal:  J Natl Cancer Inst       Date:  1972-07       Impact factor: 13.506

Review 4.  Tissue injury and delayed-type hypersensitivity.

Authors:  W B Pincus
Journal:  Ann Allergy       Date:  1970-03

5.  Antigenicity of a new diethylnitrosamine-induced transplantable guinea pig hepatoma: pathology and formation of ascites variant.

Authors:  H J Rapp; W H Churchill; B S Kronman; R T Rolley; W G Hammond; T Borsos
Journal:  J Natl Cancer Inst       Date:  1968-07       Impact factor: 13.506

6.  Complications of BCG immunotherapy in patients with cancer.

Authors:  F C Sparks; M J Silverstein; J S Hunt; C M Haskell; Y H Pilch; D L Morton
Journal:  N Engl J Med       Date:  1973-10-18       Impact factor: 91.245

7.  Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma.

Authors:  S E Krown; E Y Hilal; C M Pinsky; Y Hirshaut; H J Wanebo; J A Hansen; A G Huvos; H F Oettgen
Journal:  Cancer       Date:  1978-12       Impact factor: 6.860

8.  BCG immunotherapy of malignant melanoma: summary of a seven-year experience.

Authors:  D L Morton; F R Eilber; E C Holmes; J S Hunt; A S Ketcham; M J Silverstein; F C Sparks
Journal:  Ann Surg       Date:  1974-10       Impact factor: 12.969

9.  Effective nonliving vaccine against experimental tuberculosis in mice.

Authors:  E Ribi; C Larson; W Wicht; R List; G Goode
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

10.  Intralesional immunotherapy of melanoma with BCG.

Authors:  S A Rosenberg; H J Rapp
Journal:  Med Clin North Am       Date:  1976-05       Impact factor: 5.456

View more
  2 in total

1.  [Immunotherapy of head and neck cancer. Current developments].

Authors:  P J Schuler; T K Hoffmann; T C Gauler; C Bergmann; S Brandau; S Lang
Journal:  HNO       Date:  2013-07       Impact factor: 1.284

Review 2.  Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?

Authors:  Laura Rosa Brunet; Thorsten Hagemann; Gayab Andrew; Satvinder Mudan; Aurelien Marabelle
Journal:  Oncoimmunology       Date:  2015-12-18       Impact factor: 8.110

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.